Pancreatic Cancer Research

ResearcherNew York UniversityActive in the last 2 years

Ming Cui

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8770-4585; OpenAlex author ID A5034551676. Sources: OpenAlex.

Their work

Papers
20 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
74
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 2 papers · 2019: 1 paper · 2020: 3 papers · 2021: 4 papers · 2022: 1 paper · 2023: 1 paper · 2024: 4 papers · 2025: 1 paper · 2026: 2 papers

Papers 20

  1. Cancer cell-derived sialylated IgG interacting with Siglec-7/9/10 is a potential immunotherapeutic target in pancreatic cancer. First author DOI 10.1016/j.xcrm.2026.102660↗
  2. Spatial transcriptomics defines the molecular progression, invasion and immune landscape of IPMN and IPMN-derived pancreatic cancer. Co-author DOI 10.1136/gutjnl-2025-336117↗
  3. Comparative spatial transcriptomics of pancreatic cancer with ductal and acinar origins in mouse models. Co-author DOI 10.1002/ctm2.70416↗
  4. Cancer-Derived Immunoglobulin G and Pancreatic Cancer. Co-author DOI 10.1007/978-981-97-0511-5_10↗
  5. Crosstalk between metabolic remodeling and epigenetic reprogramming: A new perspective on pancreatic cancer. Co-author DOI 10.1016/j.canlet.2024.216649↗
  6. Pancreatic cancer cell-derived migrasomes promote cancer progression by fostering an immunosuppressive tumor microenvironment. Co-author DOI 10.1016/j.canlet.2024.217289↗
  7. Robotic Versus Laparoscopic Pancreaticoduodenectomy for Pancreatic Cancer: Evaluation and Analysis of Surgical Efficacy. Co-author DOI 10.1245/s10434-024-15764-1↗
  8. Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therapy and prognosis in pancreatic cancer. Co-author DOI 10.1097/js9.0000000000000200↗
  9. GREM1 is a novel serum diagnostic marker and potential therapeutic target for pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fonc.2022.968610↗
  10. Dopamine improves chemotherapeutic efficacy for pancreatic cancer by regulating macrophage-derived inflammations. Co-author DOI 10.1007/s00262-020-02816-0↗
  11. Lymph Node Metastatic Patterns and Survival Predictors Based on Tumor Size in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s12325-021-01819-2↗
  12. Immune subtyping for pancreatic cancer with implication in clinical outcomes and improving immunotherapy. Co-author DOI 10.1186/s12935-021-01824-z↗
  13. Comprehensive Analysis of Expression, Prognostic Value, and Immune Infiltration for Ubiquitination-Related FBXOs in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fimmu.2021.774435↗
  14. Combined blockade of TGf-β1 and GM-CSF improves chemotherapeutic effects for pancreatic cancer by modulating tumor microenvironment. Co-author DOI 10.1007/s00262-020-02542-7↗
  15. High Expression of Cancer-Derived Glycosylated Immunoglobulin G Predicts Poor Prognosis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.7150/jca.39800↗
  16. CXCL5 overexpression predicts a poor prognosis in pancreatic ductal adenocarcinoma and is correlated with immune cell infiltration. Co-author DOI 10.7150/jca.40517↗
  17. Non-invasive detection of pancreatic cancer by measuring DNA methylation of Basonuclin 1 and Septin 9 in plasma. Co-author DOI 10.1097/cm9.0000000000000257↗
  18. Tumor size classification of the 8th edition of TNM staging system is superior to that of the 7th edition in predicting the survival outcome of pancreatic canc… Co-author DOI 10.1038/s41598-018-28193-4↗
  19. Tumor microenvironment participates in metastasis of pancreatic cancer. First author DOI 10.1186/s12943-018-0858-1↗
  20. c-Fos/ERK promotes the progression from pancreatic intraepithelial neoplasia to pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/or.2016.5169↗

Closest collaborators

The 25 strongest of 74 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Quan Liao · 8 shared papers, 2018–2026 · strength 1.09
  2. Yupei Zhao · 8 shared papers, 2016–2025 · strength 0.98
  3. Sen Yang · 5 shared papers, 2021–2026 · strength 0.94
  4. Qiaofei Liu · 6 shared papers, 2020–2024 · strength 0.85
  5. Lei You · 6 shared papers, 2016–2025 · strength 0.78
  6. Yalu Zhang · 5 shared papers, 2021–2024 · strength 0.75
  7. Junyi Gao · 5 shared papers, 2020–2024 · strength 0.69
  8. Quan Liao · 4 shared papers, 2020–2025 · strength 0.66
  9. Tong Li · 5 shared papers, 2020–2024 · strength 0.63
  10. Ronghua Zhang · 5 shared papers, 2018–2024 · strength 0.56
  11. Xiang Zhang · 5 shared papers, 2018–2021 · strength 0.53
  12. Joseph R. Habib · 3 shared papers, 2021–2026 · strength 0.50
  13. Xiaoyan Qiu · 1 shared paper, 2024 · strength 0.46
  14. Jingkai Liu · 4 shared papers, 2020–2021 · strength 0.46
  15. Yu-Pei Zhao · 3 shared papers, 2019–2026 · strength 0.45
  16. Mengyi Wang · 3 shared papers, 2020–2022 · strength 0.42
  17. Christopher L. Wolfgang · 2 shared papers, 2023–2026 · strength 0.39
  18. Menghua Dai · 3 shared papers, 2018–2024 · strength 0.37
  19. Jin Peng He · 2 shared papers, 2023–2025 · strength 0.37
  20. Junya Peng · 2 shared papers, 2020–2024 · strength 0.28
  21. Qiaofei Liu · 3 shared papers, 2018–2021 · strength 0.28
  22. Jorg H. Kleeff · 2 shared papers, 2020–2024 · strength 0.26
  23. Yupei Zhao · 1 shared paper, 2026 · strength 0.26
  24. Xiaoyan Qiu · 1 shared paper, 2026 · strength 0.26
  25. Xiaoding Liu · 1 shared paper, 2026 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.